CELGENE CORP(NASDAQ:CELG) stock News

CELG Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Viz Release - Mentions: AZN CTXR

The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)

4 years ago - By: Benzinga - Mentions: AMGN PFE CANF

Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug

4 years ago - By: Bloomberg

The Typical Unicorn Founder Started Their Business at 34

4 years ago - By: Bloomberg - Mentions: LYEL GS BAC JPM ...

Glaxo-Backed Lyell Immunopharma Wobbles in Trading Debut

4 years ago - By: Bloomberg - Mentions: JPM C MS

JPMorgan Hires Citi’s Chris Gartin for Health-Care Deals

5 years ago - By: Bloomberg - Mentions: BMY

Bristol Myers Deal-Linked Derivative Surges on Inspection Hopes

5 years ago - By: Bloomberg - Mentions: BMY BLUE

Bristol Myers CVR Dealt Blow as Key Drug Faces Approval Hurdle

5 years ago - By: Bloomberg - Mentions: BLUE

All-or-Nothing Bet on Bristol Drugs Goes Sour as FDA Reviews Lag

5 years ago - By: Bloomberg

Cory Booker Defeats Trump Loyalist for Second Senate Term

5 years ago - By: Bloomberg - Mentions: AMGN MNK

Surge in Drug Prices Tied to Revenue, Million-Dollar Bonuses

5 years ago - By: Bloomberg - Mentions: BMY BLUE JNJ LEGN

Bristol Myers CVR Falls as FDA Jitters Overshadow Huge Potential

5 years ago - By: Seeking Alpha - Mentions: NKTX FATE CRSP ALLO ...

Biotech IPO Nkarta triples in debut (NASDAQ:NKTX)

5 years ago - By: CNBC - Mentions: GILD MRK PFE LLY ...

AstraZeneca contacted Gilead over potential megamerger

5 years ago - By: Bloomberg - Mentions: AMGN BMY

Amgen Sales Beat Estimates as Otezla Tested for Covid Treatment

5 years ago - By: Seeking Alpha - Mentions: XLRN BMY

FDA OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept

5 years ago - By: Seeking Alpha - Mentions: XLRN BMY

FDA's OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept

5 years ago - By: Seeking Alpha - Mentions: BMY BLUE

Celgene CVR holders near finish line with bb2121 filing in U.S.

5 years ago - By: Seeking Alpha - Mentions: BMY

European advisory group backs Celgene's ozanimod for type of multiple sclerosis

5 years ago - By: Seeking Alpha - Mentions: BGNE BMY

BeiGene reports Abraxane shortage in China

5 years ago - By: Bloomberg - Mentions: BMY BIIB BLUE

All-or-Nothing Bet on New Bristol Myers Drugs Faces First Test

5 years ago - By: Seeking Alpha - Mentions: GILD AGN ABBV BMY

Gilead an acquisition target? Deep pockets required

6 years ago - By: Seeking Alpha - Mentions: NVS

Celgene withdraws enasidenib application in Europe

6 years ago - By: Bloomberg - Mentions: CVS LLY BMRN BMY ...

CELGENE CORP (CELG) Stock News